녹내장 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 성장률(CAGR) 5.5%로 102억 달러에 달할 것으로 예측됩니다. 이 예측 기간의 성장은 고령화, 녹내장 유병률 증가, 최소침습 수술에 대한 수요 증가에 의해 주도될 것으로 예측됩니다. 또한, 녹내장 위험인자인 당뇨병, 고혈압 등 질환의 유병률 증가는 녹내장 치료에 대한 수요를 더욱 증가시킬 것으로 예측됩니다. 예측 기간 동안 주요 동향으로는 진단 기술의 발전, 새로운 약물 치료의 가용성, 수술 기구의 혁신, 병용 요법의 가용성, 로봇 수술의 채택 증가 등이 있으며, 이는 모두 녹내장 관리를 보다 효과적이고 효율적으로 만드는 데 기여할 것으로 예측됩니다.
만성 안질환의 유병률 증가는 녹내장 시장의 성장을 가속할 것으로 예측됩니다. 만성 안질환은 눈에 영향을 미치는 장기적인 질환으로 지속적인 시력 장애와 불편함을 유발하고 지속적인 관리와 치료가 필요한 경우가 많습니다. 이러한 증상 증가 요인으로는 인구의 고령화, 스크린 사용 시간 증가, 생활습관의 변화, 당뇨병 및 고혈압과 같은 질병 비율 증가 등이 있습니다. 치료는 안압을 낮추고 시신경의 추가 손상을 방지하며 시력을 유지하는 데 도움이 되기 때문에 만성 안과 질환을 관리하는 데 필수적입니다. 예를 들어, 2024년 12월 영국 국민보건서비스(NHS)의 발표에 따르면, 영국에서는 200만 명 이상의 사람들이 시력 저하와 함께 생활하고 있으며, 이 숫자는 27% 증가하여 2035년에는 약 280만 명에 달할 것으로 예측됩니다. 이에 따라 만성 안질환의 유병률이 증가하여 녹내장 시장 수요를 견인하고 있습니다.
녹내장 시장의 주요 기업들은 이중 작용기전을 제공하는 Rho-kinase(ROCK) 억제제를 포함한 혁신적인 치료법 개발에 주력하고 있습니다. Rho-kinase(ROCK) 억제제는 세포 수축을 조절하는 Rho-kinase 효소를 표적으로 억제하여 안압을 낮추며, 세포 수축을 조절하는 Rho-kinase 효소를 표적으로 억제하여 안압을 낮추기 때문에 녹내장 치료에 매우 효과적입니다. 예를 들어, 2023년 7월 일본 산텐제약(본사: 일본)은 Rho-kinase(ROCK) 억제제를 발표했습니다. 일본에 본사를 둔 산텐제약은 라타노프로스트와 신규 ROCK(Rho-kinase) 억제제인 네타르스질(Netalsuzil)의 복합제(FDC)인 로클란다(Roclanda)를 영국에 출시했습니다. 안압을 낮추도록 설계되었습니다. 이 약은 프로스타글란딘 또는 네타르수질 단독요법으로 안압을 충분히 낮추지 못하는 원발성 개방각각막증 또는 안구건조증 성인 환자를 대상으로 합니다. 로클란다의 유럽 출시는 25년 만에 새로운 유형의 녹내장 치료제로서 녹내장 치료의 큰 진전을 의미한다"며 "로클란다는 네타르수딜과 라타노프로스트의 결합을 통해 해면체(전통적) 및 포도막 공막(비전통적) 경로를 통한 유출을 촉진한다"고 말했습니다. 유출을 촉진하여 안압 상승을 관리할 수 있는 종합적인 솔루션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 녹내장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 녹내장 시장 : 성장률 분석
- 세계의 녹내장 시장 실적 : 규모와 성장, 2019-2024
- 세계의 녹내장 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 녹내장 전체 시장(TAM)
제6장 시장 세분화
- 세계의 녹내장 시장 : 질환 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 개방각 녹내장
- 폐쇄각 녹내장
- 기타 병 유형
- 세계의 녹내장 시장 진단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 안압 측정
- 안저 검사
- 시야 검사
- 전방각경 검사
- 세계의 녹내장 시장 : 약제 클래스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- Beta Blockers
- Prostaglandins
- Alpha Adrenergic Agonist
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- 기타 약물 클래스
- 세계의 녹내장 시장 : 관리별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 주사
- 유리체내
- 기타 관리
- 세계의 녹내장 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 안과 클리닉
- 외래수술센터(ASC)
- 세계의 녹내장 시장 : 개방각 녹내장별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 1차 개방각 녹내장(POAG)
- 2차 개방각 녹내장
- 세계의 녹내장 시장 : 폐쇄각 녹내장별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 1차 폐쇄각 녹내장
- 2차 폐쇄각 녹내장
- 세계의 녹내장 시장 : 기타 질환 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 정상 긴장 녹내장
- 색소성 녹내장
- 가성 각막 녹내장
- 선천성 녹내장
제7장 지역별/국가별 분석
- 세계의 녹내장 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 녹내장 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 녹내장 시장 : 경쟁 구도
- 녹내장 시장 : 기업 개요
- Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- Teva Pharmaceuticals Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
- Otsuka Pharmaceutical Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
- Bausch & Lomb Corp.
- Carl Zeiss Meditec
- Santen Pharmaceuticals Co. Ltd.
- Topcon Corporation
- Thea Laboratoires
- Corza Ophthalmology
- Lumenis Ltd.
- Alcon Inc.
- Viva Bio 이노베이터
- Glaukos Corporation
- Iridex Corporation
- Nova Eye Medical Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 녹내장 시장(2029년) : 새로운 기회를 제공하는 국가
- 녹내장 시장(2029년) : 새로운 기회를 제공하는 부문
- 녹내장 시장(2029년) : 성장 전략
제36장 부록
LSH
Glaucoma refers to a group of eye conditions that damage the optic nerve, typically due to increased intraocular pressure (IOP). If left untreated, this damage can lead to progressive and irreversible vision loss, making glaucoma one of the leading causes of blindness worldwide. Early detection through regular eye exams is essential to prevent vision impairment.
The primary types of glaucoma are open-angle glaucoma, angle-closure glaucoma, and others. Open-angle glaucoma occurs when the eye's drainage angle remains open, but the trabecular meshwork becomes progressively blocked, resulting in elevated IOP. It can be diagnosed using various methods such as tonometry, ophthalmoscopy, perimetry, and gonioscopy. Treatment includes several drug classes, including beta-blockers, prostaglandins, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs. These treatments are administered through oral medications, injections, intravitreal injections, and other routes, with end users such as hospitals, ophthalmic clinics, and ambulatory surgical centers.
The glaucoma market research report is one of a series of new reports from The Business Research Company that provides glaucoma market statistics, including glaucoma industry global market size, regional shares, competitors with a glaucoma market share, detailed glaucoma market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma industry. This glaucoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glaucoma market size has grown strongly in recent years. It will grow from $7.76 billion in 2024 to $8.22 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to factors such as increasing awareness of eye health, rising healthcare spending, the growing adoption of telemedicine for eye care, expanding healthcare infrastructure, and increased government healthcare initiatives. These factors have contributed to better detection, treatment, and management of glaucoma, helping more individuals access the care they need.
The glaucoma market size is expected to see strong growth in the next few years. It will grow to $10.20 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period is expected to be driven by the aging population, rising prevalence of glaucoma, and the growing demand for minimally invasive surgeries. Additionally, the rising prevalence of conditions such as diabetes and hypertension, which are risk factors for glaucoma, will further fuel demand for glaucoma care. Major trends in the forecast period include advancements in diagnostic technologies, the availability of new drug treatments, innovations in surgical devices, the availability of combination therapies, and the increasing adoption of robotic surgeries, all of which will contribute to more effective and efficient glaucoma management.
The increasing prevalence of chronic eye conditions is expected to drive growth in the glaucoma market. Chronic eye conditions are long-lasting disorders that impact the eyes, often causing ongoing vision impairment or discomfort, necessitating continuous management or treatment. Factors contributing to the rise of these conditions include an aging population, more screen time, lifestyle changes, and higher rates of diseases such as diabetes and hypertension. Glaucoma treatment is essential for managing chronic eye conditions, as it helps lower intraocular pressure, prevents further damage to the optic nerve, and preserves vision, with untreated glaucoma potentially leading to irreversible blindness. For example, in December 2024, the National Health Service (NHS) reported that over 2 million people in the UK are living with sight loss, a number projected to grow by 27%, reaching approximately 2.8 million by 2035. As a result, the rising prevalence of chronic eye conditions is driving demand in the glaucoma market.
Leading companies in the glaucoma market are focusing on the development of innovative treatments, including Rho-kinase (ROCK) inhibitors, which provide a dual mechanism of action. These therapies reduce intraocular pressure by improving the outflow of aqueous humor and relaxing trabecular meshwork cells, making them highly effective in glaucoma treatment. Rho-kinase (ROCK) inhibitors work by targeting and blocking the Rho-kinase enzymes, which regulate cell contraction and help decrease intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., based in Japan, introduced Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, designed to lower intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is intended for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved sufficient IOP reduction with monotherapy involving prostaglandin or netarsudil. The launch of Roclanda in Europe marks the first new class of glaucoma medication in 25 years, representing a significant advancement in treatment. By combining netarsudil and latanoprost, Roclanda enhances outflow through both trabecular (conventional) and uveoscleral (unconventional) pathways, offering a comprehensive solution for managing elevated IOP.
In December 2024, Bausch + Lomb Corp., a Canada-based healthcare company, acquired Elios Vision Inc., a U.S.-based developer of minimally invasive glaucoma surgery (MIGS) procedures. The acquisition is expected to enhance Bausch + Lomb's glaucoma treatment options by providing solutions that do not require implants. This move reflects the company's commitment to advancing technologies that support eye care professionals in addressing patients' evolving needs.
Major players in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG.
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in glaucoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the glaucoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The glaucoma market consists of revenues earned by entities by providing services such as surgical services, telemedicine consultations, treatment monitoring and custom surgical planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The glaucoma market also includes sales of laser treatment devices, glaucoma drainage implants, visual field analyzers and surgical tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glaucoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on glaucoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for glaucoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glaucoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types
- 2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy
- 3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes
- 4) By Administration: Oral; Injections; Intravitreal; Other Administrations
- 5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers
- Subsegments:
- 1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma
- 2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma; Secondary Angle Closure Glaucoma
- 3) By Other Disease Types: Normal-Tension Glaucoma; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma; Congenital Glaucoma
- Companies Mentioned: Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Teva Pharmaceuticals Industries Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Glaucoma Market Characteristics
3. Glaucoma Market Trends And Strategies
4. Glaucoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Glaucoma Growth Analysis And Strategic Analysis Framework
- 5.1. Global Glaucoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Glaucoma Market Growth Rate Analysis
- 5.4. Global Glaucoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Glaucoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Glaucoma Total Addressable Market (TAM)
6. Glaucoma Market Segmentation
- 6.1. Global Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Open Angle Glaucoma
- Angle Closure Glaucoma
- Other Disease Types
- 6.2. Global Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tonometry
- Ophthalmoscopy
- Perimetry
- Gonioscopy
- 6.3. Global Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Beta Blockers
- Prostaglandins
- Alpha Adrenergic Agonist
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Other Drug Classes
- 6.4. Global Glaucoma Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injections
- Intravitreal
- Other Administrations
- 6.5. Global Glaucoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- 6.6. Global Glaucoma Market, Sub-Segmentation Of Open Angle Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Primary Open Angle Glaucoma (POAG)
- Secondary Open Angle Glaucoma
- 6.7. Global Glaucoma Market, Sub-Segmentation Of Angle Closure Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Primary Angle Closure Glaucoma
- Secondary Angle Closure Glaucoma
- 6.8. Global Glaucoma Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Normal-Tension Glaucoma
- Pigmentary Glaucoma
- Pseudoexfoliative Glaucoma
- Congenital Glaucoma
7. Glaucoma Market Regional And Country Analysis
- 7.1. Global Glaucoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Glaucoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Glaucoma Market
- 8.1. Asia-Pacific Glaucoma Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Glaucoma Market
- 9.1. China Glaucoma Market Overview
- 9.2. China Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Glaucoma Market
- 10.1. India Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Glaucoma Market
- 11.1. Japan Glaucoma Market Overview
- 11.2. Japan Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Glaucoma Market
- 12.1. Australia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Glaucoma Market
- 13.1. Indonesia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Glaucoma Market
- 14.1. South Korea Glaucoma Market Overview
- 14.2. South Korea Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Glaucoma Market
- 15.1. Western Europe Glaucoma Market Overview
- 15.2. Western Europe Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Glaucoma Market
- 16.1. UK Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Glaucoma Market
- 17.1. Germany Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Glaucoma Market
- 18.1. France Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Glaucoma Market
- 19.1. Italy Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Glaucoma Market
- 20.1. Spain Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Glaucoma Market
- 21.1. Eastern Europe Glaucoma Market Overview
- 21.2. Eastern Europe Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Glaucoma Market
- 22.1. Russia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Glaucoma Market
- 23.1. North America Glaucoma Market Overview
- 23.2. North America Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Glaucoma Market
- 24.1. USA Glaucoma Market Overview
- 24.2. USA Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Glaucoma Market
- 25.1. Canada Glaucoma Market Overview
- 25.2. Canada Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Glaucoma Market
- 26.1. South America Glaucoma Market Overview
- 26.2. South America Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Glaucoma Market
- 27.1. Brazil Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Glaucoma Market
- 28.1. Middle East Glaucoma Market Overview
- 28.2. Middle East Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Glaucoma Market
- 29.1. Africa Glaucoma Market Overview
- 29.2. Africa Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Glaucoma Market Competitive Landscape And Company Profiles
- 30.1. Glaucoma Market Competitive Landscape
- 30.2. Glaucoma Market Company Profiles
- 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Teva Pharmaceuticals Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Glaucoma Market Other Major And Innovative Companies
- 31.1. Otsuka Pharmaceutical Co. Ltd.
- 31.2. Sun Pharmaceutical Industries Ltd.
- 31.3. Cipla Limited
- 31.4. Bausch & Lomb Corp.
- 31.5. Carl Zeiss Meditec
- 31.6. Santen Pharmaceuticals Co. Ltd.
- 31.7. Topcon Corporation
- 31.8. Thea Laboratoires
- 31.9. Corza Ophthalmology
- 31.10. Lumenis Ltd.
- 31.11. Alcon Inc.
- 31.12. Viva BioInnovator
- 31.13. Glaukos Corporation
- 31.14. Iridex Corporation
- 31.15. Nova Eye Medical Ltd.
32. Global Glaucoma Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Glaucoma Market
34. Recent Developments In The Glaucoma Market
35. Glaucoma Market High Potential Countries, Segments and Strategies
- 35.1 Glaucoma Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Glaucoma Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Glaucoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
